Celularity (CELU) Competitors $1.56 -0.09 (-5.18%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$1.54 -0.01 (-0.96%) As of 04/17/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. DBVT, IPHA, FULC, NBTX, ACTU, MOLN, RZLT, ACIU, TARA, and DMACShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include DBV Technologies (DBVT), Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Nanobiotix (NBTX), Actuate Therapeutics (ACTU), Molecular Partners (MOLN), Rezolute (RZLT), AC Immune (ACIU), Protara Therapeutics (TARA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Celularity vs. DBV Technologies Innate Pharma Fulcrum Therapeutics Nanobiotix Actuate Therapeutics Molecular Partners Rezolute AC Immune Protara Therapeutics DiaMedica Therapeutics Celularity (NASDAQ:CELU) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has more volatility and risk, CELU or DBVT? Celularity has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Does the media favor CELU or DBVT? In the previous week, DBV Technologies had 4 more articles in the media than Celularity. MarketBeat recorded 6 mentions for DBV Technologies and 2 mentions for Celularity. Celularity's average media sentiment score of 0.40 beat DBV Technologies' score of -0.23 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CELU or DBVT? DBV Technologies has a consensus target price of $22.50, suggesting a potential upside of 181.95%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CELU or DBVT? DBV Technologies received 397 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 54.22% of users gave DBV Technologies an outperform vote while only 42.11% of users gave Celularity an outperform vote. CompanyUnderperformOutperformCelularityOutperform Votes842.11% Underperform Votes1157.89% DBV TechnologiesOutperform Votes40554.22% Underperform Votes34245.78% Which has better valuation & earnings, CELU or DBVT? DBV Technologies has lower revenue, but higher earnings than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$48.20M0.77-$196.29MN/AN/ADBV Technologies$15.73M10.44-$72.73M-$5.00-1.60 Is CELU or DBVT more profitable? Celularity has a net margin of -72.72% compared to DBV Technologies' net margin of -815.73%. DBV Technologies' return on equity of -106.07% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-72.72% -119.53% -25.40% DBV Technologies -815.73%-106.07%-76.17% Do insiders and institutionals have more ownership in CELU or DBVT? 19.0% of Celularity shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 22.1% of Celularity shares are owned by insiders. Comparatively, 1.9% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryDBV Technologies beats Celularity on 10 of the 16 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.02M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8017.80Price / Sales0.77231.03379.9697.74Price / Cash0.2465.6738.2634.64Price / Book0.745.936.443.98Net Income-$196.29M$142.99M$3.21B$247.73M7 Day Performance-5.18%4.42%2.87%1.81%1 Month Performance0.97%-12.73%-8.63%-6.98%1 Year Performance-51.56%-9.48%11.46%1.37% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.2296 of 5 stars$1.56-5.2%N/A-53.0%$37.02M$48.20M0.00220Gap DownDBVTDBV Technologies2.6337 of 5 stars$7.79+6.4%$22.50+188.8%+17.4%$160.23M$15.73M-1.7380Earnings ReportAnalyst ForecastShort Interest ↑IPHAInnate Pharma1.98 of 5 stars$1.90+1.3%$11.50+505.3%-17.9%$159.28M$12.63M0.00220Positive NewsGap UpFULCFulcrum Therapeutics2.0112 of 5 stars$2.92+8.6%$8.63+195.4%-54.0%$157.62M$80M-9.42100Short Interest ↓News CoverageGap UpNBTXNanobiotix1.821 of 5 stars$3.33flat$8.00+140.2%-37.9%$156.95M$-11,609,000.000.00100Gap DownACTUActuate TherapeuticsN/A$8.00+4.4%$20.00+150.0%N/A$156.26MN/A0.0010News CoverageMOLNMolecular Partners1.6208 of 5 stars$3.86-0.3%$12.00+210.9%+1.5%$155.85M$4.97M-1.80180RZLTRezolute2.8953 of 5 stars$2.57+4.0%$24.38+848.4%-15.1%$155.58MN/A-2.1140Positive NewsGap UpACIUAC Immune2.5357 of 5 stars$1.52-2.6%$12.00+689.5%-38.8%$152.62M$27.31M-3.30140Analyst RevisionNews CoveragePositive NewsTARAProtara Therapeutics1.8158 of 5 stars$4.14+5.9%$22.50+443.5%+42.9%$152.22MN/A-1.4730Analyst ForecastNews CoveragePositive NewsGap UpDMACDiaMedica Therapeutics1.1009 of 5 stars$3.54+2.0%$8.00+126.0%+36.2%$151.71MN/A-6.3220Short Interest ↑News CoveragePositive NewsGap Up Related Companies and Tools Related Companies DBVT Competitors IPHA Competitors FULC Competitors NBTX Competitors ACTU Competitors MOLN Competitors RZLT Competitors ACIU Competitors TARA Competitors DMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CELU Stock Free CELU Stock Alerts